Evidence map›Paper›PMID 27802200›Full record

SynthesisCancer biomarkers : section A of Disease markers2016

Modern molecular biomarkers of head and neck cancer. Part I. Epigenetic diagnostics and prognostics: Systematic review.

Gintaras Juodzbalys, David Kasradze, Marco Cicciù, Aurimas Sudeikis, Laurynas Banys, Pablo Galindo-Moreno, Zygimantas Guobis

Abstract readSystematic Review
In one paragraph

Synthesis in Cancer biomarkers : section A of Disease markers, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Clinical epigenetics · 2017
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 4 countries.

Gintaras JuodzbalysDepartment of Maxillofacial Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania.
David KasradzeDepartment of Maxillofacial Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Marco CicciùDepartment of Biomedical and Dental Sciences, Morphological and Functional Images, School of Dentistry University of Messina, Messina, Italy.
Aurimas SudeikisDepartment of Maxillofacial Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Laurynas BanysDepartment of Maxillofacial Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Pablo Galindo-MorenoOral Surgery and Implant Dentistry Department, University of Granada, Granada, Spain.
Zygimantas GuobisDepartment of Dental and Oral Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania.
Lithuanian University of Health Sciences · LTUniversidad de Granada · ESUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNearly half of the head and neck cancer cases are diagnosed in late stages. Traditional screening modalities have many disadvantages. The aim of the present article was to review the scientific literature about novel head and neck cancer diagnostics - epigenetic biomarkers. EVIDENCE ACQUISITION: A comprehensive review of the current literature was conducted according to the PRISMA guidelines by accessing the NCBI PubMed database. Authors conducted the search of articles in English language published from 2004 to 2015. EVIDENCE SYNTHESIS: A total of thirty three relevant studies were included in the review. Fifteen of them concerned DNA methylation alterations, nine evaluation of abundancies in histone expressions and nine miRNA expression changes in HNC.

conclusionsConsiderable number of epigenetic biomarkers have been identified in both tumor tissue and salivary samples. Genes with best diagnostic effectiveness rates and further studying prospects were: TIMP3, DCC, DAPK, CDH1, CCNA1, AIM1, MGMT, HIC1, PAX1, PAX5, ZIC4, p16, EDNRB, KIF1A, MINT31, CD44, RARβ , ECAD. Individual histone and miRNA alterations tend to be hnc specific. Prognostic values of separate biomarkers are ambiguous. No established standards for molecular assay of head and neck cancer was found in order to elude the paradoxical results and discrepancies in separate trials.

Indexed as

AnimalsBiomarkers, TumorDNA MethylationEpigenesis, GeneticHead and Neck NeoplasmsHumansPrognosisProspective StudiesRetrospective StudiesBiomarkers, TumorDNA methylationHead and neck cancerhead and neck cancer histonehead and neck cancer miRNA

Identifiers

PMID27802200
PMCPMC13020507
OpenAlexW2531352562

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.